Core Viewpoint - A class action lawsuit has been filed against Picard Medical, Inc. (NYSE: PMI) on behalf of investors who acquired its securities between September 2, 2025, and October 31, 2025, due to allegations of a fraudulent stock promotion scheme [1] Allegations - The lawsuit alleges that Picard Medical failed to disclose involvement in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [1] - It is claimed that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [1] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] Stock Price Impact - On October 24, 2025, Picard Medical's stock price plummeted by 70%, dropping to $3.99 per share, and has since continued to decline to approximately $2.00 per share [1] Shareholder Actions - Shareholders may be eligible to participate in the class action and those wishing to serve as lead plaintiff must file their papers with the court by April 3, 2026 [1] - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [1] Legal Representation - Robbins LLP, a firm specializing in shareholder rights litigation, is representing the class action on a contingency fee basis, meaning shareholders pay no fees or expenses unless a recovery is achieved [1]

Core Viewpoint - A class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly misleading investors about its Branded Checkout offerings and growth projections [1] Group 1: Allegations and Lawsuit Details - The lawsuit claims that PayPal misrepresented its revenue outlook and growth potential while downplaying risks associated with seasonality and macroeconomic factors [1] - The complaint indicates that the growth targets set for 2027 were unrealistic and not achievable under the leadership of former CEO Chriss [1] - Following the release of disappointing financial results on February 3, 2026, PayPal's stock price dropped from $52.33 to $41.70, a decline of approximately 20.31% in one day [1] Group 2: Company Leadership Changes - The announcement of disappointing financial results coincided with the news that Enrique Lores would replace Chriss as President and CEO, effective March 1, 2026 [1] Group 3: Class Action Participation - Shareholders who purchased PayPal securities between February 25, 2025, and February 2, 2026, may be eligible to participate in the class action [1] - Interested shareholders can contact Robbins LLP to serve as lead plaintiff or remain as absent class members without participating in the case [1]

ENPH Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Enphase Energy, Inc. [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- [Robbins LLP] reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Enphase Energy, Inc. (NASDAQ: ENPH) securities between April 22, 2025 and October 28, 2025. Enphase is a global energy technology company focusing on solutions for ...

Core Viewpoint - A class action has been filed against Mereo BioPharma Group plc for allegedly misleading investors regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which did not meet their primary endpoints, leading to significant financial losses for shareholders [1][2][3]. Group 1: Allegations and Misleading Information - The complaint alleges that Mereo BioPharma provided investors with overly optimistic statements about the expected results of the Phase 3 ORBIT and COSMIC studies for setrusumab, claiming it would reduce annualized fracture rates [2]. - It is claimed that while Mereo expressed confidence in the studies, they concealed material adverse facts about the true state of the ORBIT and COSMIC programs, which ultimately failed to meet their primary endpoints [2]. Group 2: Impact on Stock Price - Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies met their primary endpoint, Mereo's American Depository Shares (ADS) plummeted from $2.31 per share to $0.29 per share, marking a decline of over 87.7% [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Mereo BioPharma, with a deadline to submit papers to serve as lead plaintiff by April 6, 2026 [4]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug setrusumab in clinical studies [1][2]. Allegations - The lawsuit claims that Ultragenyx provided overly positive information about the expected results of its Phase III Orbit and Cosmic Studies for setrusumab, which was intended to treat Osteogenesis Imperfecta (OI) [2]. - Defendants allegedly concealed material adverse facts about setrusumab's potential and the risks associated with the study protocols, leading to inflated stock prices [3]. Study Results - On December 29, 2025, Ultragenyx announced that the Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonates [4]. - Following this announcement, Ultragenyx's stock price dropped from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in one day [4]. Shareholder Actions - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [5].

Core Viewpoint - A class action has been filed against Ramaco Resources, Inc. for allegedly overstating development progress at its Brook Mine, with claims that no significant mining activity has occurred since its groundbreaking [1][2]. Allegations - The complaint states that Ramaco failed to disclose the lack of significant mining activity at the Brook Mine, which has not commenced after the groundbreaking [2]. - Wolfpack Research published a report alleging that the Brook Mine is a "hoax" and that no active mining has taken place, supported by drone footage showing no work occurring three months post-groundbreaking [3]. Stock Impact - Following the allegations and the report from Wolfpack Research, Ramaco's stock price dropped by $3.81, or 9.6%, closing at $36.01 per share on October 23, 2025 [3]. Shareholder Actions - Shareholders may be eligible to participate in the class action against Ramaco and can contact Robbins LLP for more information on serving as a lead plaintiff or remaining an absent class member [4].

Core Viewpoint - A class action lawsuit has been filed against Oracle Corporation for allegedly misleading investors about its AI infrastructure capabilities and the financial implications of its capital expenditures [1][2]. Allegations - The complaint claims that Oracle misrepresented its data center capabilities for AI infrastructure and falsely assured investors that significant capital expenditures would lead to rapid revenue growth [2]. - It is alleged that Oracle did not disclose that its AI infrastructure strategy would lead to substantial increases in capital expenditures without corresponding near-term revenue growth, raising concerns about its debt, credit rating, and free cash flow [2]. Stock Performance Impact - Following a series of disclosures from September to December 2025, Oracle's stock experienced a significant decline [3]. - On December 17, 2025, Oracle's stock price fell by $10.19 per share, approximately 5.4%, closing at $178.46 after a report indicated that Blue Owl Capital withdrew from a $10 billion funding deal for Oracle's data center due to concerns over Oracle's spending and debt levels [3]. Shareholder Actions - Shareholders may participate in the class action against Oracle and must submit their papers to the court by April 6, 2026, if they wish to serve as lead plaintiff [4]. - Shareholders can choose to remain absent class members and still be eligible for recovery without participating in the case [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Core Viewpoint - A class action has been filed against BlackRock TCP Capital Corp. for allegedly misleading investors regarding its business prospects and financial disclosures [1][2]. Group 1: Allegations - The complaint alleges that during the class period, BlackRock TCP failed to disclose that its investments were not being timely or appropriately valued [2]. - It is claimed that the company's portfolio restructuring efforts were ineffective in resolving challenged credits or improving portfolio quality [2]. - The company’s unrealized losses were reportedly understated, leading to an overstated net asset value (NAV) [2]. - Positive statements made by the defendants about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Financial Disclosure - On January 23, 2026, BlackRock TCP disclosed that its NAV per share as of December 31, 2025, was in the range of $7.05 to $7.09, which is 19% less than the previous quarter and 23.4% less than the previous year [3]. - Following this disclosure, the stock price fell by $0.76, or 12.97%, closing at $5.10 per share on January 26, 2026 [3]. Group 3: Shareholder Actions - Shareholders may be eligible to participate in the class action and must file their papers with the court by April 6, 2026, if they wish to serve as lead plaintiff [4]. - Shareholders can choose to remain absent class members without participating in the case [4].

Core Viewpoint - Robbins LLP is urging stockholders of Smart Digital Group Limited (NASDAQ: SDM) who have incurred significant losses to contact the firm regarding a class action lawsuit filed on their behalf, focusing on allegations of market manipulation and fraudulent promotion schemes [1]. Group 1: Allegations and Legal Actions - The class action lawsuit pertains to investors who purchased SDM securities between May 5, 2025, and September 26, 2025 [1]. - Allegations include that insiders facilitated a market manipulation scheme involving misinformation on social media and impersonators posing as financial professionals [1]. - It is claimed that insiders used offshore accounts to coordinate the dumping of shares during a price inflation campaign, and that SDM's public statements failed to disclose risks related to fraudulent trading [1]. Group 2: Stock Price Impact - On September 26, 2025, SDM's stock price plummeted by 86.4%, closing at $1.85 per share after a trading halt due to volatility [1]. - The SEC suspended trading of SDM securities from September 29, 2025, to October 10, 2025, due to potential manipulation linked to social media recommendations [1]. - NASDAQ also suspended trading in SDM securities on October 11, 2025, pending further information [1]. Group 3: Participation in Class Action - Shareholders interested in serving as lead plaintiffs must submit their papers by March 16, 2026, but participation is not required to be eligible for recovery [1]. - All representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [1].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired shares of uniQure N.V. between September 24, 2025, and October 31, 2025, due to allegations of misleading information regarding the FDA approval process for its drug candidate AMT-130 [1][2]. Group 1: Allegations and Impact - The lawsuit alleges that uniQure misled investors by failing to disclose that the design of its pivotal study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline for additional studies [2]. - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from its Phase I/II studies would be adequate for BLA submission, leading to a significant drop in share price from $67.69 to $34.29, a decline of over 49% [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by April 13, 2026, and participation in the case is not required to be eligible for recovery [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].